Group tasks 4

Identification of active compounds for the treatment of obesity and diabetes with licensing potential

• GT Leader: INSERM, Partner 3
• Other participants: IRB, USC, IBMC, PCB, BIOCANT
• Start date: December 2009
• End date: December 2011
• Actions:
  • Identification of Hit compounds
  • Optimization of Hit compounds
  • Analysis of pharmacological activity of the optimized compounds under A 4.2
  • Validation of active compounds in animal models
  • Analysis and conclusions
• Deliverables:
  • Group of Hit compounds no. 1,2, month 11, USC
  • Group of Hit compounds no.3 , month 18, USC
  • Validated molecules as inhibitors of SSAO or activators of Mitofusin-2 or DOR, month 33, INSERM